Results 191 to 200 of about 215,870 (306)

Managing Acute Severe Ulcerative Colitis in 2025 and Beyond. [PDF]

Curr Gastroenterol Rep
Goyal MK, Hassan SA, Berinstein JA.
europepmc   +1 more source

Assessing the Effect of Adalimumab in Granuloma Annulare: A Case Series and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Granuloma annulare (GA) is a benign granulomatous skin disorder for which standardized treatment guidelines are lacking due to limited evidence. Adalimumab, a TNF‐α inhibitor, shows promise as a therapeutic option due to its potential to disrupt GA granulomas.
Adriana Caixinha Valorenzos, Line Kibsgaard, Trine Bertelsen   +2 more
wiley   +1 more source

Pyroptosis in ulcerative colitis: biomarkers and therapeutic targets. [PDF]

J Biomed Sci
Cruz H, Shah P, Wohlgemuth N, Ketchum R, Nassif I, Hu CA.   +5 more
europepmc   +1 more source

Characteristics and Clinical Outcomes of Patients With Hidradenitis Suppurativa (HS) Treated With Bimekizumab: A Canadian Retrospective Chart Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterised by painful nodules, abscesses, and draining and non‐draining tunnels. Currently, there are two biologics approved in Canada for the treatment of moderate‐to‐severe HS, adalimumab (anti‐TNF) and secukinumab (anti‐IL‐17A).
Irina Turchin, Tracey Brown‐Maher, Hélène Veillette, David O. Croitoru, Kyle Cullingham   +4 more
wiley   +1 more source

Epidemiologic survey of ulcerative colitis and crohn's disease in Japan using claim data. [PDF]

Sci Rep
Shitara Y, Maeda-Minami A, Ishikawa H, Mutoh M, Mano Y.   +4 more
europepmc   +1 more source

Bronchiectasis associated with ulcerative colitis relapse after lung transplantation: a case report. [PDF]

ERJ Open Res
Nassurally F, Pencreach E, Hirschi S, Vallat L, Rimelen V, Dégot T, Furstenberger M, Rahli M, Kessler R, Falcoz PE, Olland A, Tacquard C, Chenard MP, Renaud-Picard B.   +13 more
europepmc   +1 more source

Therapeutic Options for IgA Pemphigus in Patients Refractory to Dapsone

JEADV Clinical Practice, EarlyView.
ABSTRACT IgA pemphigus is a rare autoimmune blistering disorder with limited therapeutic guidance available due to its rarity and complex presentation. This comprehensive analysis evaluates the therapeutic outcomes of 67 published patients, emphasising the significant role of dapsone as the first‐line treatment.
Lorenz Frasheri, Marta Dechant, Tilo Biedermann   +2 more
wiley   +1 more source

Characteristics of gut microbiota and metabolites in patients with ulcerative colitis with fatigue. [PDF]

World J Gastroenterol
Liu ZX, Liu XY, Tan WW, Zhang WB, Zhang YL, Zheng L, Dai YC.   +6 more
europepmc   +1 more source

Corrigendum to "Discordance between patients' perception and endoscopic assessment of disease activity in ulcerative colitis". [PDF]

Ther Adv Gastroenterol
europepmc   +1 more source

MicroRNAs as multifaceted regulators and therapeutic targets in ulcerative colitis. [PDF]

Front Immunol
Wang X, Jiang N, Yin W, Cui X.
europepmc   +1 more source